In The Press

Israeli startup looks to develop blood pressure finger monitor

08/06/2017

Israel’s BiPS Health is working on bracelet device for continuous checking of vital parameters Tel Aviv-based startup BiPS Health is looking to change the way patients’ vital signs are monitored at hospitals and at home. The firm is developing a medical device that enables the constant monitoring of various vital parameters, including blood pressure, blood […] Read More

Kalytera Completes Acquisition of Talent Biotechs

16/02/2017

Lead program in Graft versus Host Disease (“GvHD”), a life-threatening condition that can occur following stem cell or bone marrow transplantation Four Phase 2 clinical studies evaluating CBD in the prevention and treatment of GvHD Orphan drug designations (“ODD”) granted in the U.S. and Europe Advancing towards FDA Phase 2b clinical studies Kalytera Therapeutics, Inc. […] Read More

OPKO purchases Inspiro Medical

22/04/2014

חברת אופקו (OPKO Health) שמרכזה בארה”ב, חתמה על הסכם לרכישת Inspiro Medical מפתח-תקווה, אשר פיתחה טכנולוגיית החדרת תרופות אל דרכי הנשימה. המוצר המרכזי של החברה הוא מכשיר Inspiromatic, המשפר את החדרת התרופה אל דרכי הנשימה התחתונות. המכשיר כולל מיקרו-בקר וחיישן זרימה, אשר מבקרים את קצב אספקת התרופה ומיקרו-משאבה המזרימה את חלקיקי החומר המרפא אל דרכי […] Read More

MediWound prices IPO at $14, the low end of the range

20/03/2014

By Renaissance Capital, March 20, 2014, 08:37:20 MediWound, which is developing treatments for severe burns and  other hard-to-heal wounds, raised $70 million by offering 5.0  million shares at $14, the low end of the $14 to $16 range.  MediWound plans to list on the NASDAQ under the symbol MDWD.  Credit Suisse, Jefferies and BMO Capital Markets […] Read More

OPKO Health acquires Prolor Biotech for $480 million

24/05/2013

Prolor Biotech develops proprietary versions of proteins already approved for medical therapy, such as human growth hormone, and helps with commercialization. The Israeli biomedical company Prolor Biotech has been sold to OPKO Health for $7 a share, giving the company a value of $480 million, both companies announced Wednesday. Although a final agreement was signed, […] Read More

XTL Biopharmaceuticals Files Application for Listing on the NASDAQ

04/06/2012

XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (the “Company”), a biopharmaceutical development company, announced today that it has filed an application for relisting its ADRs on the NASDAQ Stock Exchange. The Company and its advisors believe it currently is in compliance with the criteria for the NASDAQ listing (subject to additional qualitative criteria of the […] Read More

XTL Biopharmaceuticals Ltd. Signs Letter of Intent to Acquire a Drug Development Company

30/05/2012

XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (hereinafter, “XTL”), a biopharmaceutical development company, announced yesterday that on April 12, 2012, it signed a non-binding letter of intent to acquire a company (hereinafter, the “Target Company”). Pursuant to the letter, XTL intends to acquire all of the share capital of the Target Company in consideration for […] Read More

Prolor Biotech to raise $75m on AMEX

08/04/2012

Prolor Biotech Inc. (AMEX: PBTH; TASE: PBTH) has filed with the US Securities and Exchange Commission (SEC) to raise a gross $75 million in shares in offerings. Prolor, which is developing longer-lasting versions of commercial medicines, has $13 million in cash, which it says will be sufficient at least through the end of the year. The […] Read More